ANGO · Angiodynamics Inc
$15.85
+0.19 (+1.21%)
At close · Aug 14
Market Cap
$655.12M
Shares
41.33M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| James Clemmer | CEO | $5,494,285 |
| James C. Clemmer | President, CEO | $5,494,285 |
| Stephen Trowbridge | EVP, CFO Lawrence T. Weiss SVP & Chief Legal Officer | $2,161,797 |
| Laura Piccinini | SVP & GM, Cardiovascular and International | $1,369,426 |
| Warren Nighan | SVP & GM, Global Supply Chain, Quality and Regulatory Affairs Stock Awards: The stock awards column represents aggregate grant date fair value of restricted stock unit awards and performance share awards granted in the respective fiscal year as computed in accordance with FASB ASC Topic 718, Compensation - Stock Compensation. Accordingly, the grant date fair value of restricted stock units was determined by multiplying the number of restricted stock units by the closing stock price on the date of grant, while the grant date fair value of performance share awards was determined using a Monte Carlo simulation. The assumptions used in the valuation of stock-based awards are discussed in Note 13 to our Audited Consolidated Financial Statements included in our Annual Report on Form 10-K for the fiscal year ended May 31, 2025. The table below shows the grant date fair value of the performance share awards included in the stock awards column for each year, and the maximum grant date value assuming that the highest level of performance conditions was achieved: --- Name | $1,165,146 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| James C. Clemmer | President, CEO | $5,005,971 |
| James Clemmer | CEO | $5,005,971 |
| Stephen Trowbridge | EVP, CFO | $1,822,254 |
| Laura Piccinini | SVP & GM, Endovascular Therapies and International | $1,229,380 |
| Chad T. Campbell | SVP & GM, Global Oncology and Vascular Access | $1,012,551 |
| Warren Nighan | SVP & GM, Global Supply Chain, Quality and Regulatory Affairs Stock Awards: The stock awards column represents aggregate grant date fair value of restricted stock unit awards and performance share awards granted in the respective fiscal year as computed in accordance with FASB ASC Topic 718, Compensation - Stock Compensation. Accordingly, the grant date fair value of restricted stock units was determined by multiplying the number of restricted stock units by the closing stock price on the date of grant, while the grant date fair value of performance share awards was determined using a Monte Carlo simulation. The assumptions used in the valuation of stock-based awards are discussed in Note 14 to our Audited Consolidated Financial Statements included in our Annual Report on Form 10-K for the fiscal year ended May 31, 2024. The table below shows the grant date fair value of the performance share awards included in the stock awards column for each year, and the maximum grant date value assuming that the highest level of performance conditions was achieved: | $995,082 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| James C. Clemmer | President, CEO | $3,983,691 |
| James Clemmer | CEO | $3,983,691 |
| Stephen Trowbridge | EVP, CFO | $1,249,879 |
| Laura Piccinini | SVP & GM, Endovascular Therapies and International | $843,436 |
| David D. Helsel | SVP, Global Operations and R&D | $785,625 |
| Chad T. Campbell | SVP & GM, Global Oncology and Vascular Access | $778,036 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| James C. Clemmer | President, CEO | $5,659,728 |
| James Clemmer | CEO | $5,659,728 |
| Laura Piccinini | SVP & GM, International Stock Awards: The stock awards column represents aggregate grant date fair value of restricted stock unit awards and performance share awards granted in the respective fiscal year as computed in accordance with FASB ASC Topic 718, Compensation - Stock Compensation. Accordingly, the grant date fair value of restricted stock units was determined by multiplying the number of restricted stock units by the closing stock price on the date of grant, while the grant date fair value of performance share awards was determined using a Monte Carlo simulation. The assumptions used in the valuation of stock-based awards are discussed in Note 14 to our Audited Consolidated Financial Statements included in our Annual Report on Form 10-K for the fiscal year ended May 31, 2023. The table below shows the grant date fair value of the performance share awards included in the stock awards column for each year, and the maximum grant date value assuming that the highest level of performance conditions was achieved: | $1,628,976 |
| Stephen Trowbridge | EVP, CFO | $1,530,727 |
| Chad T. Campbell | SVP & GM, Global Oncology and Vascular Access | $1,030,609 |
| David D. Helsel | SVP, Global Operations and R&D | $1,023,657 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| James Clemmer | CEO | $4,045,913 |
| James C. Clemmer | President, CEO | $4,045,913 |
| Stephen Trowbridge | EVP, CFO | $1,406,713 |
| David D. Helsel | SVP, Global Operations and R&D | $960,366 |
| Warren Nighan | SVP, Quality and Regulatory Affairs | $897,166 |
| Chad T. Campbell | SVP & GM, Vascular Access and Oncology | $853,864 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| James Clemmer | CEO | $3,116,631 |
| James C. Clemmer | President, CEO | $3,116,631 |
| Michael Greiner | — | $1,278,767 |
| Stephen Trowbridge | EVP, CFO | $1,075,639 |
| Scott Centea | SVP and GM, Peripheral Vascular | $841,368 |
| David D. Helsel | SVP, Global Operations and R&D | $769,356 |
| Brent J. Boucher | — | $716,526 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| James C. Clemmer | President, CEO | $3,001,490 |
| James Clemmer | CEO | $3,001,490 |
| Former EVP | CFO | $1,355,365 |
| David D. Helsel | SVP, Global Operations and R&D | $958,262 |
| Stephen Trowbridge | EVP, CFO | $941,399 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| James C. Clemmer | President, CEO | $2,742,621 |
| James Clemmer | CEO | $2,742,621 |
| Former EVP | CFO | $1,043,037 |
| David D. Helsel | SVP, Global Operations and R&D | $826,829 |
| Stephen Trowbridge | EVP, CFO | $718,616 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Karen A. Licitra | Class III director | Appointed | 2024-11-15 |
| Wesley E. Johnson, Jr. | Class III director | Appointed | 2024-11-15 |
| Lorinda A. Burgess | Class III director | Appointed | 2024-11-15 |
| James Clemmer | Class I director | Appointed | 2024-02-13 |
| Jan Stern Reed | new chair of the Nominating, Compliance and Corporate Governance Committee | Appointed | 2024-02-13 |
| James Clemmer | Class II director | Resigned | 2024-02-13 |
| Wesley Johnson | new chair of the Audit Committee | Appointed | 2024-02-13 |
| Dennis Meteny | member of the Board of Directors | Retired | 2024-01-22 |
| David D. Helsel | Senior Vice President of Global Operations and R&D | Resigned | 2024-01-05 |
| Jan Stern Reed | Class II director | Appointed | 2023-11-16 |
| Howard W. Donnelly | Class II director | Appointed | 2023-11-16 |
| James C. Clemmer | Class II director | Appointed | 2023-11-16 |
| Eileen O. Auen | Class II director | Appointed | 2023-11-16 |
| Lorinda Burgess | Class III director | Appointed | 2023-07-24 |
| Michael Tarnoff | Class I director | Appointed | 2022-11-04 |
| Dennis Meteny | Class I director | Appointed | 2022-11-04 |
Key facts
CIK
1275187
CUSIP
03475V101
13F (30d)
150 filings
150 filers
Visit website
Investor relations